Precirix NV
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.
2
Funding Rounds
$130.9m
Money raised
Overview
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.
Funding
Funding series
Funding Series Analysis
The company Precirix NV has raised a total of $130.87m in funding over 2 rounds.
Key Insights:
- Precirix NV Series B round, March 2022: $88.57m
- Camel-IDS funding round, November 2018: $42.3m
Precirix NV Series B round, March 2022
$88.57m
Camel-IDS funding round, November 2018
$42.3m
Industries
Precirix NV is active in the following industries: